Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Legal / IP Policy / Regulatory

China’s Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight

Fineline Cube May 8, 2026
Company Drug

Wuhan YZY Biopharma’s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment

Fineline Cube May 8, 2026
Company Drug

Guangdong Zhongsheng Pharma Reports Positive Phase IIb Results for First-in-Class ZSP1601 in Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis Reversal Potential

Fineline Cube May 8, 2026
Company Medical Device

Vazyme Biotech Secures NMPA Nod for Two RSV Antigen Detection Kits

Fineline Cube Aug 8, 2024

Vazyme Biotech Co., Ltd (SHA: 688105), a biotechnology company based in China, has announced that...

Company Deals

Eisai and SEED Therapeutics Join Forces on Molecular Glue Degraders for Neurodegeneration and Cancer

Fineline Cube Aug 8, 2024

Eisai Co., Ltd (TYO: 4523), a Japanese pharmaceutical company, and SEED Therapeutics Inc., a U.S....

Company Drug

Servier’s Voranigo Receives FDA Nod for IDH Inhibitor as Brain Tumor Treatment

Fineline Cube Aug 8, 2024

The U.S. Food and Drug Administration (FDA) has granted first-time approval for Voranigo (vorasidenib), a...

Company

Organon’s Q2 2024 Revenues Grow 2% YOY, Sets Sights on Fertility Business Rebound in 2025

Fineline Cube Aug 8, 2024

Organon (NYSE: OGN), a U.S.-based pharmaceutical company, has reported its financial results for the second...

Company Drug

Akeso Biopharma Initiates Phase III Clinical Trial for Cadonilimab in Hepatocellular Carcinoma

Fineline Cube Aug 7, 2024

Akeso Biopharma (HKG: 9926), a biopharmaceutical company based in China, has announced the first patient...

Policy / Regulatory

China’s NMPA Proposes New Rules for Export Drug Manufacturing and Management

Fineline Cube Aug 7, 2024

The National Medical Products Administration (NMPA) of China has issued a new set of regulations...

Company Deals

JiAnTeBo and Sanyou Biopharmaceuticals Join Forces to Discover Metabolic Disease Targets and Develop Agonistic Antibodies

Fineline Cube Aug 7, 2024

Guangdong JiAnTeBo Biotechnology Co., Ltd, a Chinese biotechnology company, has entered into a strategic partnership...

Company Deals

Sangamo Therapeutics and Genentech Join Forces to Develop Genomic Therapies for Neurodegenerative Diseases

Fineline Cube Aug 7, 2024

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company based in the U.S., has entered...

Company

Merck KGaA Posts 1.7% Q2 Growth Amid Varied Business Segment Performance

Fineline Cube Aug 7, 2024

Merck KGaA (FRA: MRK) has reported its financial results for the second quarter of 2024,...

Company

Zai Lab’s Q2 2024 Revenues Soar 47% YOY, Driven by Vyvgart and Zejula Sales

Fineline Cube Aug 7, 2024

Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a leading biopharmaceutical company based in China, has...

Company Deals

Cloudbreak Pharma Partners with Santen Pharmaceutical for CBT-001 Commercialization in Southeast Asia

Fineline Cube Aug 7, 2024

Cloudbreak Pharma Inc., a U.S.-based biopharmaceutical company, has entered into a strategic partnership with Japanese...

Company Deals

CybernaX Secures Licensing Deal with Merck KGaA for Advanced Lipid Storage Technology

Fineline Cube Aug 7, 2024

CybernaX, a biotechnology company based in Nanjing, has entered into a comprehensive licensing agreement with...

Company Deals

Shanghai Vitalgen BioPharma Partners with Novoprotein to Commercialize AaCas12bMax Gene Editor

Fineline Cube Aug 7, 2024

Shanghai Vitalgen BioPharma Co., Ltd, a specialist in cell and gene therapy based in China,...

Company Drug

Walvax Biotechnology’s HPV Vaccine Price Cut Sparks Potential Market Price War in China

Fineline Cube Aug 7, 2024

Walvax Biotechnology Co., Ltd (SHE: 300142) has significantly reduced the price of its bivalent human...

Company Deals

Mabwell Bioscience Partners with Cristália for Biosimilar Denosumab in Brazil

Fineline Cube Aug 7, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has entered...

Company Deals

Daiichi Sankyo and MSD Broaden Partnership to Co-Develop T-Cell Engager MK-6079

Fineline Cube Aug 7, 2024

Daiichi Sankyo (TYO: 4568), a Japanese pharmaceutical company, has announced an expansion of its strategic...

Company

Bayer AG’s Q2 2024 Global Group Sales Rise 3.1%, Driven by Pharmaceuticals and Consumer Healthcare

Fineline Cube Aug 7, 2024

Bayer AG (OTCMKTS: BAYZF), a multinational pharmaceutical and life sciences company headquartered in Germany, has...

Company Drug

Antengene’s Xpovio Receives NDA Approval in Malaysia for Multiple Myeloma Treatment

Fineline Cube Aug 6, 2024

Antengene Corp., Ltd (HKG: 6996), a biopharmaceutical company based in China, has announced the approval...

Company Medical Device

Israeli Hair Transplant Innovator Hairstetics Launches First Procedure in Asia at Hainan Hospital

Fineline Cube Aug 6, 2024

Hairstetics, an Israeli innovator in the non-absorbable polyamide hair transplant sector, has achieved a milestone...

Company Drug

Hotgen Biotech’s SGC001 Receives NMPA Approval for Clinical Trials in Myocardial Infarction

Fineline Cube Aug 6, 2024

Hotgen Biotech Co., Ltd (SHA: 688068), a biopharmaceutical company based in China, has announced that...

Posts pagination

1 … 313 314 315 … 662

Recent updates

  • Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance
  • Zai Lab Reports Q1 2026 Revenue Decline Amid Zejula Impact from Centralized Procurement, Offset by Xacduro Growth
  • Viatris Reports 8% Revenue Growth in Q1 2026 Fueled by Greater China Surge and Brand Portfolio Strength
  • Gilead Sciences Reports 4% Revenue Growth in Q1 2026 Driven by HIV Portfolio Strength and Trodelvy Expansion
  • Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance

Company

Zai Lab Reports Q1 2026 Revenue Decline Amid Zejula Impact from Centralized Procurement, Offset by Xacduro Growth

Company

Viatris Reports 8% Revenue Growth in Q1 2026 Fueled by Greater China Surge and Brand Portfolio Strength

Company

Gilead Sciences Reports 4% Revenue Growth in Q1 2026 Driven by HIV Portfolio Strength and Trodelvy Expansion

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.